Compression of paroxetine hydrochloride hemihydrate into immediate-release tablet cores places the particle-size distribution of the API and the order of addition in the dry-blend sequence ahead of almost every other process variable. In a typical low-dose formulation with a tablet core mass of 200 mg and a nominal active content of 20 mg paroxetine base, the drug load is 10.0% w/w; below 5.0% w/w the blend is classified as a low-dose system under production conditions and segregation during bin-to-press transfer becomes the dominant content-uniformity risk. A 27-station rotary tablet press equipped with 9.5 mm round standard concave tooling and operating at 45–65 rpm requires a free-flowing blend with a Carr index below 25.0 and a Hausner ratio below 1.25. Paroxetine hydrochloride hemihydrate as received can have a broad particle-size distribution and a D90 above 212 µm; when this occurs, the material is pre-blended with a diluent such as microcrystalline cellulose PH102 at a ratio of 1:5 or 1:10 before the main blend is discharged from a 600 L diffusion mixer. Sodium starch glycolate at 2.0–4.0% w/w is added to maintain a disintegration time below 15 minutes when tested in 900 mL of 0.1 N hydrochloric acid at 37.0°C using USP <701> disintegration apparatus. Magnesium stearate is restricted to 0.5–1.0% w/w and is screened through a 500 µm sieve before blending; lubrication time in a bin blender is held to 3–5 minutes at 24 rpm because the hydrophobic film formed by magnesium stearate raises disintegration time and lowers tensile strength at extended mixing times. Content uniformity is assessed according to USP <905> with an acceptance value of not more than 15.0 for 10 dosage units; additionally, the core blend is sampled from 10 locations in the hopper to verify that the relative standard deviation of paroxetine hydrochloride content does not exceed 5.0% before compression. Because paroxetine hydrochloride hemihydrate can exchange moisture with excipients, the compression area is maintained at 25°C ± 2°C and 35% ± 5% RH, and the core hardness is adjusted to 5–8 kp to avoid capping without producing a delayed-release core. Dissolution testing follows USP <711> Apparatus 2 at 50 rpm with 900 mL of dissolution medium selected from the product-specific monograph or bracketed across pH 1.2, 4.5, and 6.8 to establish a discriminating method; acceptance is governed by the applicable pharmacopoeial Q value rather than a single universal threshold.

Why Does Blend Uniformity Limit a 10 mg Paroxetine Hydrochloride Capsule Fill?

Hard gelatin capsule filling of paroxetine hydrochloride hemihydrate concentrates the same low-dose segregation risk into a smaller fill volume and makes the plug formation mechanism in the dosator nozzle the critical control point. For a 10 mg paroxetine base strength capsule with a total fill weight of 120 mg including the hydrochloride hemihydrate salt correction, the base load is 8.3% w/w; if the fill is reduced to 80 mg for a smaller capsule body, the base load rises to 12.5% w/w and the capacity of the diluent to buffer particle-size variability falls. A pre-blend of paroxetine hydrochloride hemihydrate and microcrystalline cellulose PH101 is prepared by geometric dilution in a 100 L bin blender at 20 rpm for 15–20 minutes, then milled through a 0.8 mm conical screen to break up agglomerates. Crospovidone is added at 2.0–4.0% w/w as an extragranular disintegrant and the final blend is lubricated with 0.5% w/w magnesium stearate. On an automatic tamping-pin capsule filler operating at 60,000 capsules per hour with size 3 hard gelatin shells, the tamping force is adjusted between 80–120 N to produce a plug height that does not exceed the capsule body length; insufficient tamping produces weight variation, while excessive tamping densifies the plug and delays disintegration beyond 15 minutes in 0.1 N HCl at 37°C. In-process controls for capsule filling include individual weight checks at 15-minute intervals and content uniformity per USP <905> on composite samples taken from the beginning, middle, and end of the run. Because paroxetine hydrochloride hemihydrate is handled under light protection, hard gelatin shells containing titanium dioxide are used, with iron oxide colourants permitted under the applicable 21 CFR colour additive listing; the finished capsules are packaged in high-density polyethylene bottles with induction-sealed caps and a desiccant canister when the stability protocol indicates moisture uptake above 2.0% after 3 months at 30°C/65% RH.

Aqueous Film Coating, Core Hardness, and Moisture Uptake in Paroxetine HCl Tablets

For film-coated paroxetine hydrochloride hemihydrate tablets, the coating step is not a cosmetic operation but a moisture-barrier and light-protection step that must be completed without raising the core moisture content above the limit defined by the hydration state of the API. The tablet cores are first dedusted and pre-warmed in a 24-inch side-vented coating pan at an inlet air temperature of 60–70°C and a pan speed of 8–12 rpm until the exhaust air relative humidity falls below 12.0%. A hydroxypropyl methylcellulose/polyethylene glycol 400 coating dispersion at 12.0–15.0% solids is sprayed through a 1.0 mm two-fluid nozzle at a spray rate of 4–8 g/min and an atomizing air pressure of 1.0–1.5 bar; the product bed temperature is maintained at 42–48°C. Spray rate is reduced if the exhaust relative humidity exceeds 15.0%, because excessive moisture uptake in the core can initiate surface softening and edge chipping, particularly when the core hardness is below 5 kp. Cores with a hardness of 5–8 kp and a friability of not more than 1.0% according to USP <1216> are robust enough to resist the mechanical stress of the rotating pan. After coating, the tablets are dried in the pan with the spray system off until the exhaust air temperature drops to 35°C or less and the loss on drying of the coated tablets, determined by halogen moisture balance at 80°C, is below 2.5%. The cured film is tested for moisture permeation under accelerated conditions at 40°C/75% RH for 4 weeks per ICH Q1A; an increase in core moisture of not more than 0.5% w/w is taken as a practical control limit. Colourants and opacifiers in the coating dispersion must conform to the applicable 21 CFR colour additive regulations or the equivalent national drug additive framework; no plasticizer migration into the tablet core is acceptable when macrogol 400 is used at levels above 1.0% of the coating solid weight.

When Reconstitution Granules for Oral Suspension Require Preservative and Buffer Control

In the development of reconstitution granules for paroxetine hydrochloride oral suspension, sedimentation volume, preservative efficacy, and pH-dependent chemical stability displace compact tensile strength as the primary quality attributes. The API is granulated with microcrystalline cellulose/carboxymethylcellulose sodium as a suspending aid, anhydrous citric acid and sodium citrate dihydrate as a buffering pair, sorbitol or sucrose as a sweetening vehicle, and a preservative system based on methylparaben and propylparaben within the concentration limits accepted by the applicable pharmacopoeia and the target market. The granules are dried to a loss on drying of not more than 1.0% w/w before filling into moisture-impermeable sachets or bottles, because residual moisture accelerates the hydrolytic degradation of paroxetine hydrochloride hemihydrate. On reconstitution with purified water to a concentration of 10 mg paroxetine base per 5 mL, the suspension pH is checked and maintained in the acidic buffer range determined for the specific approved formula; neutral and alkaline pH values are avoided because paroxetine free base has much lower aqueous solubility than the hydrochloride salt and can precipitate as a non-uniform suspended phase. Dispersed dose uniformity is assessed by a shaking protocol followed by sampling from the top, middle, and bottom of the bottle after 30 seconds and 60 seconds of shaking; the relative standard deviation of the paroxetine content should not exceed 5.0%. Preservative effectiveness is tested according to USP <51> or Ph. Eur. 5.1.3, with challenge organisms including Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, Candida albicans, and Aspergillus brasiliensis; the acceptance criteria are applied to the reconstituted suspension stored at 25°C for 28 days. The reconstituted suspension beyond-use date is assigned from stability data under ICH Q1A; a common target for preservative-containing oral suspensions is not more than 28 days at controlled room temperature, but the exact storage period is product-specific.

Parenteral dosage investigations for paroxetine hydrochloride hemihydrate begin with the constraint that no licensed paroxetine injection exists in the major pharmacopoeial markets and that the oral route remains the only widely approved path. Published data for the chronic parenteral use of paroxetine is limited; any injectable formulation is therefore an investigational preparation that must be justified under 21 CFR 312 or an equivalent clinical trial authorization, not as a routine commercial formulation. In a development-scale parenteral trial, the hydrochloride salt is dissolved in water for injection at a concentration not exceeding 20 mg/mL paroxetine base under acidic pH control, because the protonated form remains soluble while the free base precipitates as the pH rises toward physiological neutral; published data for this specific configuration is limited, so the actual working concentration must be established by solubility profiling. The solution is filtered through a 0.22 µm polyvinylidene fluoride membrane and subjected to bubble-point testing; terminal autoclaving at 121°C for 15 minutes is not recommended as a default because paroxetine hydrochloride undergoes hydrolytic degradation under prolonged thermal stress. If aseptic filtration is used, the hold time between dissolution and sterile filtration is limited to reduce the formation of oxidative degradation products; nitrogen sparging of the water for injection reduces dissolved oxygen below 2.0 mg/L. Osmolality is adjusted to 280–320 mOsm/kg with sodium chloride or mannitol, and the final pH is maintained in the acidic range determined by chemical stability and physiological tolerance. Particulate matter is controlled according to USP <788> and Ph. Eur. 2.9.19 for small-volume parenterals; insoluble particulate counts must meet light obscuration particle count limits of not more than 6000 particles per container at 10 µm and 600 particles per container at 25 µm. Because preclinical safety data for injectable excipients and long-term paroxetine exposure by the parenteral route are limited, formulation feasibility work is normally restricted to short-duration compatibility and stability screenings under ICH Q1A conditions at 2–8°C for 12 months, with pH, assay, and subvisible particle monitoring at each pull point.

Photostability Forced Degradation Under ICH Q1B Determines Primary Packaging Choices for Paroxetine HCl

Finished paroxetine hydrochloride hemihydrate dosage forms are assigned a light-protective packaging configuration only after forced photodegradation testing under ICH Q1B Option 2 is completed. The API and the formulated tablets or capsules are exposed to a total illumination of not less than 1.2 million lux hours and an integrated near ultraviolet energy of not less than 200 W·h/m² in a photostability chamber equipped with a cool white fluorescent lamp and a near-ultraviolet fluorescent lamp as defined in ICH Q1B. A photo-stable formulation demonstrates not more than 5.0% total related substances after exposure, with no individual unspecified impurity exceeding 0.2% w/w and no single specified degradation product exceeding the limit set in the corresponding pharmacopoeial monograph. If photodegradation is observed, the primary packaging is switched to opaque high-density polyethylene bottles, amber glass bottles, or PVC/PVDC/aluminium blisters, depending on the moisture vapour transmission rate and the light transmission measured at 200–800 nm. The selected blister material is tested for water vapour transmission rate according to ASTM F1249 at 38°C and 90% relative humidity; a reported water vapour transmission rate below 0.1 g/m²/day at 38°C/90% RH is a typical target for a PVDC-coated PVC base laminated to aluminium foil, but the exact threshold is set by the stability protocol. Desiccant quantity in bottle configurations is calculated from the moisture uptake of the dosage form at 40°C/75% RH and the package volume; a 1-g silica gel canister in a 100 mL high-density polyethylene bottle containing 30 tablets is a starting point, but the amount must be confirmed by sorption-desorption studies. The total related substances and paroxetine content are monitored by a stability-indicating high-performance liquid chromatographic method validated according to ICH Q2(R1), with the mobile phase and detector wavelength selected to resolve paroxetine from its principal oxidative and hydrolytic degradation products.